A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Phase of Trial: Phase I/II
Latest Information Update: 13 Jan 2018
At a glance
- Drugs Sapanisertib (Primary) ; Pazopanib
- Indications Leiomyosarcoma; Malignant-fibrous-histiocytoma; Nerve sheath neoplasms; Sarcoma; Synovial sarcoma
- Focus Adverse reactions; Therapeutic Use
- 20 Dec 2017 Status changed from suspended to recruiting.
- 14 Sep 2017 Planned primary completion date changed from 31 Jul 2017 to 1 Sep 2020.
- 07 Aug 2017 Status changed from recruiting to suspended due to unacceptable Toxicity